Glactone Pharma develops novel drugs that target STAT3, a key transcription factor signaling pathway, for the treatment of advanced and drug resistant cancers to improve the lives of cancer patients.

Glactone Pharma AB

Our vision

We strive to build strong science and robust data to deliver real and meaningful benefits to patients. Learn more about our projects.

Our mission

We develop unique small-molecule inhibitors of STAT3 (Signal Transducer and Activator of Transcription 3) to enhance the efficacy and response of immunotherapies in immuno-oncology and for the treatment of advanced drug resistant cancers.

News & press releases

Archive >

New principal owner

2019-12-09

Glactone Pharma AB’s principal owner AQILION AB is selling its entire stake in the portfolio company Glactone Pharma... [Read more]

Ny huvudägare

2019-12-09

Glactone Pharma:s huvudägare AQILION AB säljer hela sitt aktieinnehav i portföljbolaget Glactone Pharma AB till Daniel Lifveredson Invest... [Read more]